Novel Coronavirus Vaccine (mRNA-1273) Positive Interim Phase 1 Data
May 18, 2020
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company’s development of a potential vaccine against the novel coronavirus, the parameters and timing of the Phase 1 and planned Phase 2 and 3 studies of mRNA-1273, the Company’s investment in manufacturing, and the Company’s intentions regarding vaccine dose production. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could”, “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the fact that the safety and efficacy of mRNA-1273 has not yet been established; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.
SARS-CoV-2 vaccine (mRNA-1273) interim Phase 1 data

- After two doses all participants evaluated to date across the 25 µg and 100 µg dose cohorts seroconverted with binding antibody levels at or above levels seen in convalescent sera

- mRNA-1273 elicited neutralizing antibody titer levels in all eight initial participants across the 25 µg and 100 µg dose cohorts, reaching or exceeding neutralizing antibody titers generally seen in convalescent sera

- mRNA-1273 was generally safe and well tolerated

- Anticipated dose for Phase 3 study between 25 µg and 100 µg; expected to start in July

- mRNA-1273 provided full protection against viral replication in the lungs in a mouse challenge model
Accelerated research and development
SARS-CoV-2 vaccine (mRNA-1273)

January 13, 2020
Sequence for mRNA-1273 against the novel coronavirus finalized

March 16, 2020
First participant in NIH-led Phase 1 study was dosed

April 16, 2020
Award from U.S. government agency BARDA for up to $483 million to accelerate development

April 27, 2020
IND submitted to US FDA for Phase 2 study

May 1, 2020
Collaboration announced with Lonza Ltd to manufacture mRNA-1273 (goal of up to one billion doses per year)

May 6, 2020
FDA clearance to proceed with Phase 2 study

May 18, 2020
Positive interim Phase 1 data announced

July 2020
Planned Phase 3 start

1. Assuming a dose of 50 µg
**SARS-CoV-2 vaccine (mRNA-1273)**

*Phase 1 trial (run by the National Institutes of Health)*

**Key objective:** To assess the safety, reactogenicity and immunogenicity of mRNA-1273

**Study design:** Phase 1, open-label dose ranging clinical trial in males and non-pregnant females, 18 to 55 years of age

- Forty-five subjects were enrolled into one of three cohorts (25, 100 and 250 µg)
- Subjects will receive an intramuscular (IM) injection (0.5 milliliter [mL]) of mRNA-1273 on Days 1 and 29 in the deltoid muscle and will be followed through 12 months post second vaccination (Day 394)

**Primary endpoint:**
- Safety and reactogenicity of a 2-dose vaccination schedule of mRNA-1273, given 28 days apart, across 3 dosages in healthy adults

**Secondary endpoint:**
- Evaluate the immunogenicity as measured by IgG ELISA to the SARS-CoV-2 S protein following a 2-dose vaccination schedule of mRNA-1273 at Day 57

**Trial progress/details:**
- NIAID-led Phase 1 study of mRNA-1273 has completed enrollment of 3 dose cohorts (25 µg, 100 µg and 250 µg); expanded to an additional 6 cohorts of older adults and elderly adults; is being amended to include a 50 µg dose level cohort across each of the three age groups

---

**SARS-CoV-2 Phase 1 dosing regimen**

**mRNA-1273-P101 Study Design**

- **Dose level 1 (25 µg)**
  - 18-55 YOA (n=15)
- **Dose level 2 (100 µg)**
  - 18-55 YOA (n=15)
- **Dose level 3 (250 µg)**
  - 18-55 YOA (n=15)

**Data available after one vaccination at Day 29**

**Data available after two vaccinations at Day 43**

---

Slide 5
SARS-CoV-2 vaccine (mRNA-1273)

Positive interim Phase 1 data

- **Safety:** mRNA-1273 was generally safe and well tolerated, with a safety profile consistent with that seen in prior Moderna infectious disease vaccine clinical studies.
  - The sole incidence of a grade 3 adverse event in the 25 µg and 100 µg dose cohorts was a single participant at 100 µg who experienced grade 3 erythema (redness) around the injection site.
  - To date, the most notable adverse events were seen at the 250 µg dose level, comprising three participants with grade 3 systemic symptoms, only following the second dose.
  - All adverse events have been transient and self-resolving. No grade 4 adverse events or serious adverse events have been reported.

- **Immunogenicity data:** Currently available for the 25 µg and 100 µg dose level (ages 18-55) after two doses (day 43) and at the 250 µg level (ages 18-55) after one dose (day 29).
  - Dose dependent increases in immunogenicity were seen across the three dose levels, and between prime and boost within the 25 µg and 100 µg dose levels.
  - All participants ages 18-55 (n=15 per cohort) across all three dose levels seroconverted by day 15 after a single dose.
  - At day 43, two weeks following the second dose, at the 25 µg dose level (n=15), levels of binding antibodies were at the levels seen in convalescent sera (blood samples from people who have recovered from COVID-19) tested in the same assay.
  - At day 43, at the 100 µg dose level (n=10), levels of binding antibodies significantly exceeded the levels seen in convalescent sera. Samples are not yet available for remaining participants.

- **Neutralizing antibody data:** Available only for the first four participants in each of the 25 µg and 100 µg dose level cohorts.
  - Consistent with the binding antibody data, mRNA-1273 vaccination elicited neutralizing antibodies in all eight of these participants, as measured by plaque reduction neutralization (PRNT) assays against live SARS-CoV-2.
  - The levels of neutralizing antibodies at day 43 were at or above levels generally seen in convalescent sera.
SARS-CoV-2 vaccine (mRNA-1273)

Preclinical results

- Preclinical results from a viral challenge study in mice conducted in collaboration with NIAID and its academic partners are also available.

- In this study, vaccination with mRNA-1273 prevented viral replication in the lungs of animals challenged with SARS-CoV-2.

- Neutralizing titers in Phase 1 clinical trial participants at the 25 µg and 100 µg dose levels were consistent with neutralizing titers that were protective in the mouse challenge model.
SARS-CoV-2 vaccine (mRNA-1273) clinical development plan

**January 13**  
Sequence for mRNA-1273 against the novel coronavirus finalized

**March 16**  
First participant in NIAID-led Phase 1 study was dosed

**May 6**  
FDA clearance to proceed with Phase 2 study

**May 18**  
Positive interim Phase 1 data announced

---

**2020**

- **Phase 1 (March)**
- **Phase 2 (to begin soon)**
- **Phase 3 (expected to begin in July)**

**Accelerated strategy**
- Phase 2 study to begin shortly after *early Phase 1 safety data* became available
- Phase 3 *expected to begin once early Phase 2 safety data* are available, subject to finalization of the clinical trial protocol
Late stage development for SARS-CoV-2 vaccine (mRNA-1273)

- Expected to begin in 2Q20
- Study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart
- Subject to receive placebo, a 50 μg or a 100 μg dose at both vaccinations; the Phase 2 study was amended based on the interim Phase 1 data
- 600 healthy participants; two cohorts of adults ages 18-55 years (n=300) and older adults ages 55 years and above (n=300)

Finalizing protocol for Phase 3 study; expected to begin in July of 2020

1. Previous study design protocol provided that each participant would be assigned to receive placebo, a 50 μg or a 250 μg dose at both vaccinations
Our mission
To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.